Search results for " Combination"

showing 10 items of 923 documents

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003

INTRODUCTION Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly a…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyMelperoneVenlafaxine HydrochlorideVenlafaxinePharmacologyMethylationPharmacokineticsOral administrationCytochrome P-450 CYP2D6 InhibitorsInternal medicineDextrorphanmedicineHumansDrug InteractionsPharmacology (medical)AgedRetrospective StudiesChemistryVenlafaxine HydrochlorideGeneral MedicineDextromethorphanMiddle AgedCyclohexanolsButyrophenonesPsychiatry and Mental healthEndocrinologyCytochrome P-450 CYP2D6Drug Therapy CombinationFemaleDrug MonitoringReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Addition of a second opioid may improve opioid response in cancer pain: preliminary data

2004

Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The…

AdultMalecancer painMaximum Tolerated DosePain medicineAnalgesicPainRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleStatistics Nonparametriclaw.inventionPharmacotherapyRandomized controlled triallawNeoplasmsMedicineHumansTerminally IllProspective StudiesKarnofsky Performance StatusAdverse effectAgedPain MeasurementProbabilityTerminal CareDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedClinical trialAnalgesics OpioidFentanylTreatment OutcomeOncologyOpioidopioid responseAnesthesiaopioid treatmentDrug Therapy CombinationFemaleCancer painbusinessmedicine.drug
researchProduct

Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study

2012

Healthcare-associated pneumonia (HCAP) has been proposed as a new category of pneumonia distinct from community-acquired pneumonia (CAP). A multicenter observational study in 2008 finds that patients with HCAP have a mortality rate significantly higher than patients with CAP, and a worse outcome is associated at logistic regression analysis with a low adherence to empirical antibiotic therapy recommended by ATS/IDSA guidelines. We designed a prospective interventional study to establish whether administration of a broad-spectrum antibiotic therapy consistent with the 2005 ATS/IDSA guidelines has an effect on the clinical outcome of hospitalized patients with HCAP. All patients with HCAP pro…

AdultMalecommunity-acquired pneumonia; broad-spectrum empirical therapy; healthcare-associated pneumonia; multidrug-resistant pathogens; antibiotic therapymedicine.medical_specialtyCarbapenemcommunity-acquired pneumoniaSettore MED/09 - Medicina InternaAdolescentLogistic regressionNOYoung AdultCommunity-acquired pneumoniaDrug Resistance Multiple BacterialInternal medicinePneumonia BacterialInternal Medicinemedicineantibiotic therapyHumanspneumoniaProspective StudiesYoung adultIntensive care medicineProspective cohort studyAgedAged 80 and overCross Infectionbusiness.industryMortality ratehealthcare-associated pneumoniaHealthcare-associated pneumonia Community-acquired pneumonia Antibiotic therapy Multidrug-resistant pathogens Broad-spectrum empirical therapybroad-spectrum empirical therapyLength of StayMiddle Agedmedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheAnti-Bacterial AgentsPneumoniamultidrug-resistant pathogensItalyPractice Guidelines as TopicEmergency MedicineDrug Therapy CombinationFemaleObservational studybusinessantibiotic therapy; pneumoniamedicine.drug
researchProduct

A Prospective Randomized Study of Corticosteroids as Adjuvant Drugs to Opioids in Advanced Cancer Patients

2007

This randomized controlled study evaluated the role of corticosteroids as adjuvants to opioid therapy in 76 advanced cancer patients with pain who requiring strong opioids. Patients were divided in 2 groups. Group O received conventional opioid treatment. Group OS received dexamethasone (8 mg orally) along with conventional treatment. Pain and symptom intensity, sense of well-being, and opioid escalation index and distress score were recorded at weekly intervals until death. No differences in pain intensity, opioid consumption, and opioid escalation index were found in 66 patients who survived 33 to 37 days. Corticosteroids did not provide significant additional analgesia to opioids, but p…

AdultMalecorticosteroidmedicine.medical_treatmentAnti-Inflammatory Agentslaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trial030502 gerontologylawNeoplasmsmedicineHumansProspective Studiesopioids in advanced cancer patientsprospective randomized studyProspective cohort studyDexamethasoneAgedPain MeasurementAged 80 and overAnalysis of VarianceChemotherapyadjuvant drugDose-Response Relationship Drugbusiness.industryPalliative CareGeneral MedicineMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidChemotherapy Adjuvant030220 oncology & carcinogenesisAnesthesiaDrug Therapy CombinationFemale0305 other medical scienceCancer painbusinessAdjuvantFollow-Up Studiesmedicine.drugAmerican Journal of Hospice and Palliative Medicine®
researchProduct

Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism

1991

Objective The response to subcutaneous (SC) gonadotropin replacement therapy, using human chorionic gonadotropin (hCG) and human menopausal gonadotropin (hMG) or hCG alone, was evaluated in male hypothalamic hypogonadism. Design Sixteen patients with hypothalamic hypogonadism were treated with gonadotropins for induction of puberty and normalization of spermatogenesis. The results were analyzed retrospectively. Setting The study was carried out in a clinical endocrinology department providing tertiary care and in private practices of endocrinology. Patients Eight patients with idiopathic hypogonadotropic hypogonadism and eight patients with Kallmann's syndrome in prepubertal or early pubert…

AdultMaleendocrine systemmedicine.medical_specialtyMenotropinsAdolescentmedicine.drug_classmedicine.medical_treatmentChorionic GonadotropinInjections IntramuscularHuman chorionic gonadotropinSemen qualityHypogonadotropic hypogonadismInternal medicineTestisHumansMedicineEunuchismTestosteroneSexual MaturationSpermatogenesisRetrospective StudiesChemotherapybiologyurogenital systembusiness.industryHypogonadismObstetrics and Gynecologymedicine.diseaseSpermEndocrinologyReproductive MedicineHMG-CoA reductasebiology.proteinDrug Therapy CombinationGonadotropinbusinessSpermatogenesisFertility and Sterility
researchProduct

The Effects of an Essential Oil and an Amine Fluoride/Stannous Fluoride Mouthrinse on Supragingival Plaque Regrowth

2008

Background: The side effects of chlorhexidine (CHX) have stimulated the search for alternative antiplaque agents such as amine fluoride/stannous fluoride (ASF) and essential oils (EO). The aim of the study was to investigate the plaqueinhibiting effects of two commercially available mouthrinses containing ASF and EO, respectively. Methods: The study was an observer-masked, randomized, 5 · 5 Latin square cross-over design, balanced for carryover effects, involving 15 volunteers in a 4-day plaque regrowth model. A 0.12% CHX rinse and a saline solution served as positive and negative controls, respectively. On day 1, subjects received professional prophylaxis, suspended oral hygiene measures, …

AdultMalefluoride/therapeutic useDosemedicine.medical_treatmentDental PlaqueMouthwashesPainDentistryDental plaqueOral hygienelaw.inventionTaste Disorderschemistry.chemical_compoundSettore MED/28 - Malattie OdontostomatologichelawLatin squareDental plaque/prevention and controlOils VolatilemedicineHumansSingle-Blind MethodAminesSalineEssential oilCross-Over StudiesTerpenesbusiness.industryChlorhexidineDental Plaque IndexChlorhexidineessential oils/ therapeutic useoral hygienemedicine.diseaseSalicylatesDrug CombinationschemistryAnti-Infective Agents LocalTin FluoridesPeriodonticsFemaleMouth DiseasesbusinessFluoridemedicine.drugJournal of Periodontology
researchProduct

Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors

2015

Abstract Since chronic hepatitis C has mostly become curable, issues concerning choice and allocation of treatment are of major concern. We assessed the foremost ethical issues in hepatitis C virus therapy with 1st generation protease inhibitors using the personalist ethical framework within the health technology assessment methodology. Our aim was to identify values at stake/in conflict and to support both the physicians’ choices in hepatitis C therapy and social (macro-) allocation decision-making. The ethical assessment indicates that: (1) safety/effectiveness profile of treatment is guaranteed if its use is restricted to the patients subgroups who may benefit from it; (2) patients shoul…

AdultMalehepatitis C virusmedicine.medical_specialtyPathologyCost-Benefit AnalysisHepatitis C virusDecision MakingProtease InhibitoreducationAlternative medicineHepacivirusDirect-acting antiviralmedicine.disease_causeAntiviral AgentsSettore MED/02 - Storia Della MedicinaResource (project management)medicineHumansProtease InhibitorsEthics MedicalEthichealth technology assessmentCost-Benefit AnalysiDeferralIntensive care medicineEthical frameworkdirect-acting antiviralsAgedAntiviral AgentSettore MED/12 - GastroenterologiaHepaciviruHepatologybusiness.industryGastroenterologyHealth technologyHepatitis CMiddle AgedSettore MED/43 - MEDICINA LEGALEmedicine.diseaseHepatitis CethicsFirst generationDrug Therapy CombinationFemaleHepatitis C virubusinessHuman
researchProduct

Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.

2018

Aims Aim of this study was to associate concentration of naltrexone and its major active metabolite 6β-naltrexol in blood with therapeutic outcome during treatment with naltrexone in subjects with alcohol dependence. Treatment with the μ-opiate receptor antagonist naltrexone has been shown to reduce craving for alcohol and alcohol intake in patients suffering from alcohol dependence. Short summary This article shows the use of therapeutic drug monitoring in alcohol dependent patients, who are treated with naltrexone. The plasma concentrations of naltrexone and 6β-naltrexol showed high inter-individual variability. They were predictive for treatment response, as they correlated significantly…

AdultMalemedicine.drug_classAcamprosateNarcotic Antagonists030508 substance abuseCravingAlcoholPharmacologyNaltrexone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodReference ValuesmedicineHumansActive metaboliteCravingEthanolmedicine.diagnostic_testbusiness.industryAlcohol dependenceGeneral MedicineMiddle AgedReceptor antagonistNaltrexoneAlcoholismTreatment OutcomechemistryTherapeutic drug monitoringDrug Therapy CombinationFemalemedicine.symptomDrug Monitoring0305 other medical sciencebusiness030217 neurology & neurosurgerymedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis.

2003

To identify predictive factors of response to interferon alpha (IFN-alpha) plus ribavirin therapy in patients with chronic hepatitis C (CHC), the presence of lymphadenopathy (LyA) of the hepatoduodenal ligament and other variables were investigated. A total of 110 patients with histologically proven CHC were enrolled in this study. Ultrasound (US) was performed at the start and end of therapy and 6 months after stopping therapy. At baseline, LyA was present in 35 (43.7%) of 80 patients with alanine aminotransferase (ALT) values and grading was significantly higher than in the LyA-negative group. LyA was more frequent in nonresponders (nonR) than in relapsers (relR) or sustained responders (…

AdultMalemedicine.medical_specialtyAcoustics and UltrasonicsEnd of therapyBiophysicsAlpha interferonGastroenterologyAntiviral Agentschemistry.chemical_compoundInternal medicineRibavirinmedicineHumansUltrasound Lymphadenopathy Chronic hepatitis C Treatment Predictive factors.Radiology Nuclear Medicine and imagingProspective StudiesAlanine aminotransferaseLymph nodeLymphatic DiseasesUltrasonographyHepatitisRadiological and Ultrasound Technologybusiness.industryRibavirinInterferon-alphaHepatoduodenal ligamentHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureLogistic ModelsTreatment OutcomechemistryDrug Therapy CombinationFemaleLymphbusinessUltrasound in medicinebiology
researchProduct

EPIDEMIOLOGICAL SURVEILLANCE OF VISCERAL LEISHMANIASIS IN SICILY, ITALY

1997

Abstract Visceral leishmaniasis (VL) is endemic in Sicily. Although it is a notifiable disease, there is evidence that the actual number of cases is higher than that reported. In 1987, a regional reference center for active surveillance of VL was established and it recorded a total of 284 cases through 1995, a mean of 31.5 cases/year and about four-fold more than previously reported. Of the 284 cases, 150 (53%) were children (≤ 14 years of age), and of the 134 adults, 39 (29%) were coinfected with human immunodeficiency virus (HIV). The commonest viscerotropic zymodeme of Leishmania infantum, MON 1, was identified in 40 (93%) of 43 HIV-negative and eight (57%) of 14 HIV-positive patients. A…

AdultMalemedicine.medical_specialtyAdolescentAllopurinolMeglumine antimoniateNotifiable diseaseAntiprotozoal AgentsHIV InfectionsCohort StudiesAge DistributionMeglumineRecurrenceAmphotericin BVirologyInternal medicineAmphotericin BEpidemiologyOrganometallic CompoundsmedicineAnimalsHumansLeishmania infantumSex DistributionChildSicilyleishmaniasisAgedMeglumine Antimoniatebiologybusiness.industryInfantLeishmaniasisMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryInfectious DiseasesVisceral leishmaniasisChild PreschoolLeishmaniasis VisceralAntimonialDrug Therapy CombinationFemaleParasitologyLeishmania infantumbusinessmedicine.drug
researchProduct